epocrates logo
epocrates logo
epocrates logo
  • Home
  • Search
  • Tools
  • Saved
  • 0
    Notifications
  • CME
  • Help & Feedback
  • About Us
  • Business Solutions

The clinical information you need, at your fingertips.

Medical News for You

Journal Article Synopsis

NUTRITION 2026

2h

Plant-forward diet cuts heart risk, even at modest adherence

Postmenopausal women derive meaningful cardiovascular benefits even with imperfect adoption of the plant-forward Planetary Health Diet. . .

Government Health Agency Alert

CDC/FDA

1d

Nine-state Cyclospora outbreak grows as cases near 2,000

CDC and FDA trace outbreak to recalled iceberg lettuce as cases and hospitalizations continue to rise. . .
Journal Article Synopsis

BMJ

2d

Hair loss more common with GLP-1s than other diabetes drugs

Modestly higher alopecia rates showed up in adults with type 2 diabetes on GLP-1 receptor agonists. . .

Government Health Agency News

Drug pipeline

2d

Retatrutide heads toward FDA filing after positive phase 3 obesity trial results

The investigational triple agonist produced up to 22.6% average weight loss in patients with obesity complicated by type 2 diabetes or cardiovascular disease. . .
Journal Article Synopsis

J Couns Psychol

2d

Accepting career uncertainty tied to more meaningful work

Workers who made peace with imperfect information and trusted their own intuition reported a stronger sense of purpose. . .
Journal Article Synopsis

Neurology

2d

Plasma exchange linked to strong recovery in rare neurologic disease

Meta-analysis suggests plasmapheresis may improve outcomes in steroid-refractory or severe MOGAD attacks, with few safety concerns. . .

Journal Article Synopsis

Neurology

2d

Earlier deaths from MS reveal racial disparities

National study highlights the need for earlier diagnosis and better cardiovascular risk management to improve long-term outcomes. . .

Government Health Agency News

FDA

3d

FDA approves Jideytro, next-generation ROS1 inhibitor for previously treated NSCLC

Zidesamtinib was designed to overcome resistance mutations and improve brain penetration, addressing key limitations of earlier ROS1-targeted treatments. . .

Internally Generated Content

IAC 2026

3d

Once-weekly HIV pill clears phase 3 hurdle

Investigational islatravir/lenacapavir regimen maintained viral suppression through 48 weeks, potentially offering the first once-weekly oral treatment option for people with HIV. . .

Journal Article Synopsis

Cochrane Database Syst Rev

3d

Exercise eases hip OA pain, but perhaps not noticeably

Pooled trial data show small average improvements in pain and function with exercise for hip osteoarthritis. . .
Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

About Us

Features

Business Solutions

Help & Feedback

Terms of Use

Privacy Policy

visit epocrates on instagram
visit epocrates on facebook
visit epocrates on youtube
visit epocrates on twitter
visit epocrates on linkedIn

© 2026 epocrates, Inc.

download epocrates on app storedownload epocrates on google play

Do not sell or share my personal information

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information